Literature DB >> 10464885

Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD?

M Cazzola, M G Matera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10464885     DOI： 10.1016/s0954-6111(99)90017-3

Source DB:  PubMed          Journal:  Respir Med        ISSN： 0954-6111            Impact factor:   3.415


× No keyword cloud information.
  5 in total

Review 1.  β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives.

Authors:  Maria Gabriella Matera; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

Review 2.  Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

Authors:  B Jarvis; A Markham
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease.

Authors:  M Cazzola; F Di Perna; S Centanni; C Califano; C F Donner; M D'Amato; G D'Amato
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 4.  Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

5.  Long acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials.

Authors:  Don Husereau; Vijay Shukla; Michel Boucher; Shaila Mensinkai; Robert Dales
Journal:  BMC Pulm Med       Date:  2004-08-31       Impact factor: 3.317
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.